09:11 AM EST - Eupraxia Pharmaceuticals Inc. : Announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System in its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. These data were also presented this week at the Digestive Disease Week conference in Chicago. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $9.88.
